Transitioned to a recurring revenue model and strengthened CRO presence, but revenue declined and losses persisted. Operational and financial structure improved, with new patents and scientific validation supporting future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.